Skip to main content

GERN

Stock
Health Care
Biotechnology

Performance overview

GERN Price
Price Chart

Forward-looking statistics

Beta
1.36
Risk
84.76%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Company info

SectorHealth Care
IndustryBiotechnology
Employees216
Market cap$2.7B

Fundamentals

Enterprise value$623.0M
Revenue$116.3M
Revenue per employee
Profit margin-119.54%
Debt to equity45.40

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.21
Dividend per share
Revenue per share$0.18
Avg trading volume (30 day)$14M
Avg trading volume (10 day)$14M
Put-call ratio

Macro factor sensitivity

Growth+3.3
Credit+8.5
Liquidity-2.2
Inflation+0.1
Commodities+0.8
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio-17.88
Price to sales7.83
P/E Ratio-17.88
Enterprise Value to Revenue5.36
Price to book3.40

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates

Geron (GERN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.09 per share a year ago.

Zacks Investment Research (May 7, 2025)
Recap: Geron Q2 Earnings

Shares of Geron (NASDAQ:GERN) rose 2.5% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 50.00% over the past year to ($0.09), which missed the estimate of ($0.08).

Benzinga (August 16, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free